Abvc Biopharma, Inc.
ABVC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.05
KIRA · Stoqly’s AI analyst, in plain words
- Abvc Biopharma, Inc. had $0.3M of revenue in fiscal 2025, down 41.9% on the year before. Over five years, revenue changed −9.3% a year on average.
- Its operating margin was −2,416.0%, down 1,492.7 pts: of every 100 in sales, about −2,416 is left after running the business.
- Abvc Biopharma, Inc. lost $7.9M in fiscal 2025.
- Abvc Biopharma, Inc. owes $0.0M more than it holds in cash.
Market cap
$27.4M
P/E
—
Revenue
$0.3M
Net income
−$7.9M
Free cash flow
—
Operating margin
−2,416.0%
Abvc Biopharma, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−41.9%
No. Sales fell 41.9% last year.
Does it make a profit?
−2,671.8%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Abvc Biopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- ABVC BIOPHARMA, INC.
- CIK
- 0001173313
Abvc Biopharma, Inc. · ABVC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.4M | $1.0M | $0.2M | $0.5M | $0.3M |
| Revenue growth | −26.3% | 172.6% | −84.3% | 234.4% | −41.9% |
| Gross margin | 98.6% | 70.5% | −98.2% | 99.8% | — |
| Operating margin | −3,290.1% | −1,558.5% | −4,440.1% | −923.3% | −2,416.0% |
| Net income | −$12.8M | −$16.4M | −$7.8M | −$4.9M | −$7.9M |
| Net margin | −3,608.4% | −1,693.5% | −5,110.3% | −962.1% | −2,671.8% |
| Diluted EPS | −$0.51 | −$5.19 | −$1.80 | −$0.42 | −$0.39 |
| Cash | |||||
| Cash from operations | −$7.6M | −$7.4M | −$4.2M | −$1.8M | −$3.0M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | — | — |
| Free cash flow | −$7.6M | −$7.5M | −$4.2M | — | — |
| FCF margin | −2,140.3% | −775.2% | −2,761.2% | — | — |
| Share count change | 27.1% | −87.4% | 36.9% | 169.3% | 72.3% |
| Debt and strength | |||||
| Cash and short-term investments | $5.9M | $0.2M | $0.1M | $0.3M | $0.7M |
| Debt incl. finance leases | $1.6M | $1.9M | $0.9M | $0.8M | $0.8M |
| Shareholders' equity | $8.8M | $3.1M | $1.6M | $1.2M | $11.1M |
| Current ratio | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
| Interest coverage | −51.5x | −51.4x | −5.2x | −5.7x | −17.2x |
| Returns and quality | |||||
| Return on capital | −203.4% | −247.1% | −231.0% | −212.0% | −50.8% |
| Return on equity | −209.1% | −275.0% | −334.8% | −352.7% | −128.2% |
| Return on tangible equity | −145.2% | −530.0% | −501.1% | 428.9% | −71.2% |
| Piotroski F-score | 4 | 3 | 3 | 6 | 4 |
| Altman Z'' | −11.1 | −30.5 | −36.2 | −37.6 | −13.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Abvc Biopharma, Inc. · ABVC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.05 a share, the company is worth $27.4M.
Source: SEC EDGAR XBRL filings (CIK 0001173313). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.